Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics to Provide Genomic Antibodies Products to Berlex Under Expanded Supply Agreement

NEW YORK, April 20 (GenomeWeb News) - Strategic Diagnostics will provide Genomic Antibodies' antibodies to Berlex as part of an amendment of its supply agreement with the drug maker, the companies said today in a statement.

Genomic Antibodies' process will reduce the time it takes to produce antibodies for Berlex, Matthew Knight, Strategic Diagnostics president and CEO, said in the statement.

The antibodies can be directed against "traditionally difficult antigen targets, such as transmembrane proteins, membrane-associated proteins, and highly conserved proteins, which will help Berlex to identify and market new pharmaceuticals more quickly," he said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.